General Catalyst recently launched a $670 million healthcare investment fund. The fund, called Health Assurance Fund II, seeks to carry on the mission of the venture capital firm’s first healthcare-focused fund, but with a new focus on health system partnerships.
Add an Ask the Investor breakfast meeting to your INVEST Digital Health agenda and gain insights from investors from DaVita Venture Group, Noro-Moseley Partners, Providence Ventures, FirstTrust Capital, Blue Cross Blue Shield Kansas, and Flare Capital Partners.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Digital health startups raised $10.3 billion across 329 deals during the first half of 2022. This putts the sector on track to rake in $21 billion this year, about $8 billion less than the total amount it raised in 2021. The market boom has ended, but the digital health investment space has not come crashing down by any means, according to a recent report.
Technological advances are moving drug discovery work to computers, but experimental medicines still must be tested in animals. Startup Manifold Bio is developing technology that enables the testing of hundreds of molecules in a single mouse, bringing drug hunters valuable in vivo data much earlier in the drug discovery process.
OSF Ventures — the investment arm of Peoria, Illinois-based OSF HealthCare — gained a new leader last week when Mayank Taneja took the helm. In the role, Taneja oversees $250 million in assets across three funds. The venture capital arm is currently focused on investing in solutions to take care outside the four walls of a hospital and increase workforce retention, he said.
During first three months of 2022, biopharma tech companies raised less money and made fewer deals than they did in the last three months of 2021. A volatile stock market is exacerbating the trend.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Cell and gene therapy research has been hot the past few years but the overall market has cooled down in recent months. During the World Medical Innovation Forum in Boston, a panel of venture capitalists discussed capital formation and what biotech firms need to do to win over investors and advance their research.
Winners were selected across each of the four tracks of the startup pitch contest: care coordination and value-based care; diagnostics 2.0; pharmatech; and remote patient monitoring and smart devices.
Venture capital investment in healthcare startups is continuing at a steady pace. Is it too much? Is a correction coming? Three investors offered their perspectives during a panel discussion at MedCity News’s INVEST conference in Chicago.
LifeMine Therapeutics, a company that analyzes fungal genomes to find molecules that have potential as new medicines, has raised $175 million in financing. Among the investors is GlaxoSmithKline, which is teaming up with the biotech startup in a multi-target drug discovery alliance.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
In our first in-person event in two years, the MedCity INVEST conference March 28-30 at the Ritz Carlton Hotel in Chicago, there will be many opportunities to connect with startups, investors and potential collaboration partners.
Diagnostics developer Sherlock Biosciences has advanced its molecular diagnostic capabilities, which can now produce faster results on low-cost devices. The startup will use its Series B round of funding to expand the reach of its technology, potentially placing it directly in the hands of consumers around the world.
On the heels of a job report showing triple digit job growth at venture-backed companies, National Venture Capital Association has urged Democrat and Republican leaders on Capitol Hill to create a visa for foreign-born entrepreneurs as part of the Let Immigrants Kickstart Employment Act of 2021.
The IPO market has cooled, but biotech companies are still finding cash through private deals. Here’s a recap of the financing activity in the week leading up to President’s Day.
Register for MedCity INVEST at the Ritz Carlton in Chicago and be part of the conversation on healthcare investment trends. Attendees will also be able to take part in networking opportunities and hear health tech, medtech and pharma tech startups pitch to investors.